Colorectal Cancer Diagnostics Market: Introduction
Colorectal cancer starts within the colon or the rectum. These cancers can also be called
colorectal carcinoma, colon cancer, or rectal cancer, reckoning on where they begin.
Colorectal carcinoma and rectal cancer are often grouped because they need several
features in common.
Colorectal cancer typically affects older adults; however, it can happen at any age. It always
begins as small, noncancerous (benign) clumps of cells called polyps that form on the inside
of the colon. Over time, several of these polyps can become colon cancers.
If colorectal carcinoma develops, numerous treatments are available to control it, including
surgery, radiotherapy, and drug treatments such as chemotherapy, targeted therapy, and
Colorectal cancer has a significantly high incidence and prevalence rate, worldwide. Primary
causes of colorectal cancer are lifestyle disorders, aging, and diet.
According to the World Health Organization (WHO), a rise of around 70% is predicted in
colorectal cancer cases across the globe, by 2030
Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and could
be a major reason behind morbidity and mortality throughout the globe. CRC is the second-
most-common reason behind cancer-related deaths within the U.S.
Looking for a complete analysis of competitive dynamics? , Get the PDF Sample Copy of this
Key Drivers, Restraints, and Opportunities of Colorectal Cancer Diagnostics Market
The World Cancer Research Fund estimates colorectal cancer to be the third-most occurring
form of cancer around the world. In 2012, more than 1 million people were diagnosed with
colorectal cancer. Majority of these were reported in developed countries, and the number
is anticipated to increase in the near future. These incidences of colorectal carcinoma have
boosted the demand for their diagnostics worldwi